Christopher Lopez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christopher Lopez has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Jacques Simkins
Jackson Memorial Hospital Miami Florida USA
1 shared publication - Julia Bini Viotti
Division of Infectious Diseases Miami Transplant Institute University of Miami Miami Florida USA
1 shared publication - Lubna Osman
Infectious Diseases, Mount Sinai Medical Center, 4300 Alton Rd, Miami Beach, FL 33140, USA
1 shared publication - Shweta Anjan
Miami Transplant Institute, Jackson Health System, Miami, FL 33136, USA
1 shared publication - Yoichiro Natori
Division of Infectious Disease, Department of Medicine, University of Miami Miller School of Medicine , Miami, Florida
1 shared publication
Latest Publications
- Open Access
- 16 March 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (3) , 596
Therapy of Mycobacterium abscessus Infections in Solid Organ Transplant Patients
Mycobacterium abscessus complex (MABC), a rapidly growing Mycobacterium, is one of the most common causes of non-tuberculous mycobacteria (NTM) infections in the United States of America, and it has been associated with a wide spectrum of infections in immunocompetent and immunosuppressed individuals. Eradicating MABC is very challenging, even with prolonged combination therapies. The management of MABC infections in solid organ transplant (SOT) patients is usually complex given their net state of immunosuppression, associated comorbidities, and potential drug–drug interactions, among other things. In this manuscript, we discussed the antimicrobial management of pulmonary and extrapulmonary MABC infections. In addition, we reviewed promising novel therapies such as clofazimine, omadacycline, bedaquiline, and inhaled tigecycline that could join the existing antimicrobial armamentarium to fight this infection associated with significant morbidity and mortality. However, further studies are needed, especially among the immunocompromised host.
- 16 March 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (3) , 596
Open AccessTherapy of Mycobacterium abscessus Infections in Solid Organ Transplant Patients
Mycobacterium abscessus complex (MABC), a rapidly growing Mycobacterium, is one of the most common causes of non-tuberculous mycobacteria (NTM) infections in the United States of America, and it has been associated with a wide spectrum of infections in immunocompetent and immunosuppressed individuals. Eradicating MABC is very challenging, even with prolonged combination therapies. The management of MABC infections in solid organ transplant (SOT) patients is usually complex given their net state of immunosuppression, associated comorbidities, and potential drug–drug interactions, among other things. In this manuscript, we discussed the antimicrobial management of pulmonary and extrapulmonary MABC infections. In addition, we reviewed promising novel therapies such as clofazimine, omadacycline, bedaquiline, and inhaled tigecycline that could join the existing antimicrobial armamentarium to fight this infection associated with significant morbidity and mortality. However, further studies are needed, especially among the immunocompromised host.